The Indian government plans to cap trade margins on non-scheduled cancer medicines at 30% of their maximum retail price (MRP), a move expected to reduce prices of some treatments by as much as 70% and ease the financial burden on patients. The proposed intervention would extend trade-margin restrictions across the non-scheduled anti-cancer category as well.
The measure will cover around 110 anti-cancer medicines, including 35 patented drugs, and apply to branded and generic products, as well as domestically manufactured and imported medicines, according to official sources cited by IANS on Thursday.
The policy is expected to take effect later in October. Government estimates suggest patients could save around ₹2,500 crore annually as lower trade margins translate into reduced retail prices.
Cancer treatment often involves prolonged medication, repeated hospital visits and substantial out-of-pocket expenditure. By restricting the margins available across the medicine distribution chain, the government aims to curb excessive mark-ups without disrupting the availability of essential treatments.
The potential price reduction will vary by medicine. The estimated cut of up to 70% does not mean every affected drug will become 70% cheaper.
New Price Controls Expand Beyond Selected Cancer Drugs
Under the proposed framework, trade margins on all non-scheduled anti-cancer medicines will be limited to 30% of the MRP, irrespective of brand, generic status or country of manufacture.
The distinction between scheduled and non-scheduled medicines is important. Scheduled drugs are subject to price controls under India’s drug-pricing framework, while non-scheduled medicines are generally not subject to the same ceiling-price mechanism. The proposed intervention would extend trade-margin restrictions across the non-scheduled anti-cancer category.
The policy builds on a similar intervention introduced in 2019, when the government capped trade margins on selected cancer medicines to address excessive mark-ups.
The latest measure broadens that approach by covering the entire category of non-scheduled anti-cancer medicines rather than a limited selection of products.
For patients, the practical impact will depend on the existing retail price of each medicine, the margins charged across its distribution chain and the extent to which the new limits are reflected in revised MRPs.
₹2,500 Crore in Potential Annual Savings
The government estimates that the measure could generate annual savings of approximately ₹2,500 crore for patients. The intervention is intended to improve affordability for people who require expensive cancer medicines over extended periods.
However, the actual savings for individual patients will depend on the medicines prescribed and the price reductions implemented. The government has not provided a drug-by-drug breakdown of the expected cuts in the information cited by IANS.
The policy’s effectiveness will also depend on implementation, compliance by manufacturers and distributors, and the availability of affected medicines at the revised prices.
The planned cap represents a wider effort to address the cost of cancer care by targeting pricing practices within the pharmaceutical supply chain. Its impact should become clearer once the government formally implements the measure and the revised prices of individual medicines are established.